Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid and Gazyva in Relapsed Indolent NHL
NCT01995669Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2014
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, obinutuzumab in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2014; status: completed.
02
Drugs
lenalidomideobinutuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)marginal zone lymphoma (MZL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01995669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01995669.